UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that KYGEVVI® has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults and ...
The global population is ageing and this demographic shift has profound effects on haemostasis, notably a progressive tilt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback